Phio Pharmaceuticals Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed on November 9, 2023, by Phio Pharmaceuticals Corp., a Delaware corporation. The filing reports financial results for the period ended September 30, 2023, and announces a significant clinical milestone regarding the Company's lead asset, PH-762.
Key Financial Metrics
The filing references a press release (Exhibit 99.1) containing the financial results for the period ended September 30, 2023. However, the text of this 8-K does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Investors must refer to the attached press release for detailed financial data.
Material Changes and Clinical Updates
- Clinical Milestone: The Company announced that the first patient has been dosed in its U.S. Phase 1b clinical trial.
- Asset: The trial involves intratumoral PH-762.
- Indications: The study targets patients with cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma.
Guidance, Outlook, and Risks
The filing does not contain specific forward-looking guidance, updated financial outlook, or detailed risk factors within the body of the 8-K text. The information regarding financial results and the clinical trial is incorporated by reference from the attached press releases (Exhibits 99.1 and 99.2).
Key Facts for Investor Verification
- Verify the specific financial figures (cash position, burn rate, and revenue) in the attached press release (Exhibit 99.1) as they are not listed in this summary text.
- Confirm the enrollment criteria and primary endpoints of the U.S. Phase 1b trial for PH-762 in the clinical trial press release (Exhibit 99.2).
- Review the Company's cash runway and funding requirements given the progression to Phase 1b trials.